Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial
Ahmed O. Kaseb(The University of Texas MD Anderson Cancer Center), Padmanee Sharma(The University of Texas MD Anderson Cancer Center), Kristen Carter(The University of Texas MD Anderson Cancer Center), Jing Sun(The University of Texas MD Anderson Cancer Center), Kanwal Raghav(The University of Texas MD Anderson Cancer Center), Vittorio Cristini(Houston Methodist), Robert A. Wolff(The University of Texas MD Anderson Cancer Center), Courtney Nicholas(The University of Texas MD Anderson Cancer Center), James C. Yao(The University of Texas MD Anderson Cancer Center), Ryan Sun(The University of Texas MD Anderson Cancer Center), James P. Allison(The University of Texas MD Anderson Cancer Center), Shalini S. Yadav(The University of Texas MD Anderson Cancer Center), Aliya Qayyum(The University of Texas MD Anderson Cancer Center), Sonali Jindal(The University of Texas MD Anderson Cancer Center), Sunyoung S. Lee(The University of Texas MD Anderson Cancer Center), Divya Sakamuri(The University of Texas MD Anderson Cancer Center), Lianchun Xiao(The University of Texas MD Anderson Cancer Center), Fei Duan(The University of Texas MD Anderson Cancer Center), Betül Gök Yavuz(Hacettepe University Hospital), Ching‐Wei D. Tzeng(The University of Texas MD Anderson Cancer Center), Yehia I. Mohamed(The University of Texas MD Anderson Cancer Center), Sreyashi Basu(The University of Texas MD Anderson Cancer Center), Jean‐Nicolas Vauthey(The University of Texas MD Anderson Cancer Center), Laura Beretta(The University of Texas MD Anderson Cancer Center), Asif Rashid(American International University-Bangladesh), Hop Sanderson Tran Cao(The University of Texas MD Anderson Cancer Center), Elshad Hasanov(The Ohio State University Wexner Medical Center), Li Xu(The University of Texas MD Anderson Cancer Center), Yun Shin Chun(The University of Texas MD Anderson Cancer Center)
Cited by 255
Related Papers
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
|Journal of Clinical Oncology|2007|3.9k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Posthepatectomy liver failure: A definition and grading by the International Study Group of Liver Surgery (ISGLS)
|Surgery|2011|2.3k
Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
|New England Journal of Medicine|2012|2.1k